• metastatic/advanced - breast cancer (mBC) 1
• cervical cancer (CC)
• classical Hodgkin lymphoma (cHL)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab alone

• versus all
• vs immune chekpoint inhibitors
• vs others immune checkpoint inhibitors
• vs brentuximab vedotin

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  R/R cHL - second line or more (L2);